Galen in upfront $4.5million deal with Novo Research for US rights for Synera pain relief patch

11 July 2013

Canada’s Nuvo Research (TSX: NRI) today announced that its wholly owned subsidiary, ZARS Pharma, has entered into a license agreement for Galen US to acquire exclusive rights to market and sell Nuvo's Synera patch in the USA.

Under the terms of the agreement, Galen has made an upfront payment to Nuvo of $4.5 million. Nuvo, which focuses on products for the treatment of pain, will receive royalties of 10% of net sales and is eligible to receive a $5 million milestone payment upon gross annual sales reaching $25 million and a further $5 million upon gross annual sales reaching $50 million.

Synera is a topical patch that combines lidocaine, tetracaine and heat and is approved by the US Food and Drug Administration to provide local dermal analgesia for superficial venous access and superficial dermatological procedures, such as excision, electrodessication and shave biopsy of skin lesions.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK